82 Treatment of advanced and disseminated non small lung cancer (NSCLC) in elderly patients: Results of the MIC regimen

Pj, Souquet; Bombaron, P.; Brunel-Crova, J.; Bernard, Jean‐Pierre

doi:10.1016/s0169-5002(97)89361-0

Cited by 12 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the toxicity profile of these regimens limits their use in the elderly populations who are less likely to tolerate its potential toxicity than younger patients due to the age-related reduction in the functional reserve of many organs and due to the presence of comorbid conditions [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)

et al. 2005

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)

et al. 2005

View full text Add to dashboard Cite

“…The study randomized only the main cause of treatment discontinuation. The authors did not advise the MIC regimen in the elderly [58]. On the contrary, a further retrospective trial showed that cisplatinbased chemotherapy (cisplatin plus vindesine or cisplatin plus mitomycin C plus vindesine) was feasible and associated with a higher response rate (44% vs 28%) in the elderly [59].…”

Section: Platin-based Chemotherapymentioning

confidence: 97%

Chemotherapy of Non-small Cell Lung Cancer in Elderly Patients

Gridelli¹,

Maione²,

Colantuoni³

et al. 2002

CMC

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) may be considered typical of advanced age. More than 50% of NSCLC patients are diagnosed over the age of 65 and approximately one-third of all patients with non-small cell lung cancer (NSCLC) are over the age of 70. Elderly patients tolerate chemotherapy poorly as compared to their younger counterparts, because of the progressive reduction of organ function and comorbidities related to age. For this reason, these patients are often not considered eligible for aggressive cisplatin-based chemotherapy, the standard medical treatment of advanced NSCLC. At present, for early stages of the disease there are no indications for adjuvant and neoadjuvant chemotherapy. Combined chemo-radiotherapy in locally advanced disease increases toxicity and seems to determine no survival advantage as compared to the radiation therapy alone. In advanced disease, single agent vinorelbine has proven to be active and well-tolerated, and compared to best supportive care, improves survival and perhaps even the quality of life. Gemcitabine is active and well tolerated as well. Taxanes are in advanced phase of evaluation. A phase III randomized trial showed that polychemotherapy with gemcitabine and vinorelbine does not improve any outcome as compared to single agent chemotherapy with vinorelbine or gemcitabine. In clinical practice, single agent chemotherapy should remain the standard treatment. The two main research-lines to be explored in the near future are the introduction of biological agents in the treatment schemes and the development of specifically designed schedules of cisplatin-based regimens. However, practicing a multidimensional geriatric awsessment for individualized treatment choice in NSCLC elderly patients is mandatory.

show abstract

“…Bone marrow and renal toxicities were the main causes of treatment discontinuation. The authors did not advise the MIC regimen in the elderly [107].…”

Section: Prospective Trials With Cisplatin-based Chemotherapymentioning

confidence: 98%

Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients

Rossi¹,

Maione²,

Gridelli³

2005

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) may be considered typical of advanced age. More than 50% of NSCLC patients are diagnosed at > 65 years of age and approximately one-third of all patients are > 70 years of age. Elderly patients tolerate chemotherapy poorly compared with their younger counterpart because of the progressive reduction of organ function and comorbidities related to age. For this reason, these patients are often not considered eligible for aggressive platinum-based chemotherapy, the standard medical treatment for advanced NSCLC. In clinical practice, single-agent chemotherapy should remain the standard treatment. Feasibility of platinum-based chemotherapy remains an open issue and has to be proven prospectively. Moreover, a multidimensional geriatric assessment for individualised treatment choice in NSCLC elderly patients is mandatory. This review focuses on the currently-available evidences for the treatment of elderly patients affected by advanced NSCLC with regards to the role and safety of platinum-based chemotherapy.

show abstract

82 Treatment of advanced and disseminated non small lung cancer (NSCLC) in elderly patients: Results of the MIC regimen

Cited by 12 publications

References 0 publications

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)

Chemotherapy of Non-small Cell Lung Cancer in Elderly Patients

Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients

Contact Info

Product

Resources

About